| dc.contributor.author | Bovis, F. | |
| dc.contributor.author | Kalincik, T. | |
| dc.contributor.author | Lublin, F. | |
| dc.contributor.author | Cutter, G. | |
| dc.contributor.author | Malpas, C. | |
| dc.contributor.author | Horakova, D. | |
| dc.contributor.author | Hupperts, R. | |
| dc.date.accessioned | 2020-06-21T12:26:01Z | |
| dc.date.available | 2020-06-21T12:26:01Z | |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 1352-4585 | |
| dc.identifier.issn | 1477-0970 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/10632 | |
| dc.description | 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDEN | en_US |
| dc.description | Turkoglu, Recai/0000-0001-9724-851X; Altintas, Ayse/0000-0002-8524-5087; McCombe, Pamela/0000-0003-2704-8517; Ferraro, Diana/0000-0003-4818-3806 | en_US |
| dc.description | WOS: 000485303103218 | en_US |
| dc.description.abstract | … | en_US |
| dc.description.sponsorship | European Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltd | en_US |
| dc.description.sponsorship | TEVA Neuroscience; CIHRCanadian Institutes of Health Research (CIHR); FISM (Fondazione Italiana Sclerosi Multipla)Fondazione Italiana Sclerosi Multipla (FISM); EMD; BiogenBiogen; NovartisNovartis; GenzymeGenzyme Corporation | en_US |
| dc.description.sponsorship | Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.; JS Wolinsky has served on advisory boards and data monitoring or steering committees, has consulting agreements, and has received speaker honoraria from the following: AbbVie, AcademicCME, ACTRIMS, Alkermes, Bayer HealthCare, Biogen, Bionest, Celgene, Clene Nanomedicine, CMSC, ECTRIMS, EMD Serono, Forward Pharma A/S, MA's Communications, Masters MS, MedDay Pharmaceuticals, Novartis Pharmaceuticals, Otsuka, PRIME, PTC Therapeutics, Roche Genentech, Sanofi Genzyme, Strategic Consultants International, Takeda, Teva Pharmaceuticals, and WebMD; royalties have been received for outlicensed monoclonal antibodies through UTHealth from Millipore Corporation. Claudio Solaro served as advisory board the following companies: Biogen Idec, Merck Serono, Almirall and GW Pharma. He received speaking honoraria from Biogen Idec, Merck Serono. He received research grants and support by the FISM (Fondazione Italiana Sclerosi Multipla). | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Sage Publications Ltd | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data | en_US |
| dc.type | conferenceObject | en_US |
| dc.contributor.department | OMÜ | en_US |
| dc.identifier.volume | 25 | en_US |
| dc.identifier.startpage | 788 | en_US |
| dc.identifier.endpage | 790 | en_US |
| dc.relation.journal | Multiple Sclerosis Journal | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
